NOTE 12 - SEGMENT INFORMATION

3 Months Ended

Jul. 31, 2022

Notes

NOTE 12 - SEGMENT INFORMATION

NOTE 12 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three months ended July 31, 2022 and 2021; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three months ended July 31, 2022 and 2021 is as follows: 

	Three Months Ended July 31,
	2022	2021
Revenues:
Stevioside - third party	$7,607,323	$3,775,050
Stevioside - related party	-	2,386,628
Total Stevioside	7,607,323	6,161,678
Corporate and other – third party	102,580	106,782
Corporate and other – related party	-	-
Total Corporate and other	102,580	106,782
Total segment and consolidated revenues	$7,709,903	$6,268,460
Interest expense:
Stevioside	$133,021	$70,671
Corporate and other	-	-
Total segment and consolidated interest expense	$133,021	$70,671
Depreciation and amortization:
Stevioside	$292,174	$327,668
Corporate and other	40,354	56,593
Total segment and consolidated depreciation and amortization	$332,528	$384,261
Income (loss) from continuing operations before income taxes:
Stevioside	$(254,931)	$(812,243)
Corporate and other	60,780	62,120
Total loss from continuing operations before income taxes	$(194,151)	$(750,117)

	July 31, 2022	April 30, 2022
Segment property and equipment:
Stevioside	$5,490,411	$5,854,328
Corporate and other	1,555,195	1,631,405
Total property and equipment	$7,045,606	$7,485,733